It’s time to see where artificial intelligence is genuinely being utilized in pharma.
Mike Hollan
Advertisement
Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.
Articles by Mike Hollan
Abrams discusses how both new pharma and big pharma are reacting to each other and the current market.
The company worked in partnership with Neurocode.
PicnicHealth’s CEO discusses how AI is making data more useful to the life sciences industry.
The Trinity Life Sciences managing director and head of DE&I strategy discusses recent research on the topic.
The two companies will combine assets to develop a device that make automatic adjustments.
Independence Blue Cross and Jefferson health published a study detailing the impact of such care.
The foundation donated over $1 million to these programs.
The life sciences technology company will be able to offer services to the pharmacies associated with Legacy.
Respondents said logistic reasons kept them from going to the doctor.
The company provided guidance for how people in the storm’s path can prepare ahead of time and ensure they have access to medication.
The team launched from California and rowed to one of the islands of Hawaii.
The PGDx elio plasma focus Dx offers laboratories testing options for situations where samples are hard to obtain.
The app provides users with lifestyle tips and plans based on the lifestyles of people living in regions with the highest lifespans.
Integrated Delivery Networks have impacted everything from drug launches to sales approaches.
The report also details steps that employers are taking to manage the cost of healthcare plans for employees.
The company announced that it will conduct research based on guidance from the agency.
Ouva’s AI-powered technology will be added to AvaSure’s digital platform.
The company plans to develop these treatments using it’s AI-powered platform.
MGI Tech Co. issued a statement detailing the use of its technology in improving the rates of genomic sequencing in South Africa.
An unexpected consequence of the COVID 19 pandemic has been a loss in trust of vaccines. Over the past three flu seasons, there has been a drop in vaccination rates that is alarming experts. Dr. Gregg Sylvester, chief health officer at CSL Seqirus, spoke with Pharmaceutical Executive about the causes of the decline and how important it is to get the rates back to normal.
The partnership will allow both group to expand their operations and provide more solutions to underserved communities.
The lead transformation evangelist at Celonis discusses how digital twins are becoming more prominent in the pharma industry.
Biocon Biologic’s chief commercial officer of advanced markets discusses the current market and potential trends for biosimilars.
The PBM defined its core values and what role it believes PBMS should play in the industry.
The deals leader at EY Global Life Sciences discusses how the first half of 2024 fared compared to 2023’s strong ending.
The company received the money through a government project agreement.
The AI-powered feature will provide detailed nutritional information based on photos of food taken by users.
Dx&Vx identified multiple potential drug candidates using AI-based technology.
The two companies will continue to collaborate on the use of machine learning in improving precision medicine development.
Advertisement